Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.ORCID iD: 0000-0003-3703-0062
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.ORCID iD: 0009-0005-7558-8309
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology, Research group Markus Sjöblom/Olof Nylander.ORCID iD: 0000-0002-1406-9389
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.ORCID iD: 0000-0002-7806-0447
Show others and affiliations
2025 (English)In: European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, E-ISSN 1873-3441, Vol. 211, article id 114719Article in journal (Refereed) Published
Abstract [en]

Aim: Proteolysis targeting chimeras (PROTACs) exhibit a unique and promising pharmacology. However, this comes with molecular properties exceeding the 'drug-like' rule of five chemical space, which often limits gastrointestinal absorption. This in vivo study aimed to investigate the contribution of luminal and plasma stability, intestinal effective permeability, P-glycoprotein (P-gp) efflux, and bile excretion, on the rat intestinal absorption and systemic exposure of two PROTACs, ARV-110 (812 Da, LogD7.4 4.8) and ARV-471 (724 Da, LogD7.4 4.6).

Methods: Luminal stability and effective intestinal permeability were determined directly from luminal disappearance using single-pass intestinal perfusion, with and without a protease inhibitor, or a P-gp/Cytochrome P450 CYP3A inhibitor (ketoconazole) in rats. Plasma stability was tested by in vitro incubations. Intestinal absorption, systemic exposure, and biliary excretion were examined after intraduodenal and intravenous dosing with ketoconazole or the P-gp selective inhibitor (encequidar).

Results and discussion: Both PROTACs were degraded in the intestinal lumen and in plasma by peptidases. The intestinal effective permeability in rats was moderate for ARV-110 (0.62 x 10-4 cm/s) and low for ARV-471 (0.23 x 10-4 cm/s). P-gp inhibition increased the permeability 1.6-and 2.3-fold for ARV-110 and ARV-471, respectively. After intraduodenal dosing with the P-gp inhibitors a corresponding increase in systemic exposure was observed for both PROTACs. There was only a minor difference in the increased systemic exposure induced by the two inhibitors, suggesting that the mechanisms were primarily P-gp inhibition, rather than gut-wall and hepatic extraction. Biliary excretion was a minor pathway and did not affect the absorption and systemic exposure of the PROTACs to a large extent.

Conclusion: In the rat, ARV-110 and ARV-471 were enzymatically degraded in the intestinal lumen and in plasma, and their intestinal permeability and systemic exposure seem to be reduced due to P-gp efflux.

Place, publisher, year, edition, pages
Elsevier, 2025. Vol. 211, article id 114719
Keywords [en]
PROTACs, P-glycoprotein, ARV-110 (bavdeglutamide), ARV-471 (vepdegestrant), Intestinal permeability, Pharmacokinetics
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-556609DOI: 10.1016/j.ejpb.2025.114719ISI: 001477297100001PubMedID: 40228726OAI: oai:DiVA.org:uu-556609DiVA, id: diva2:1959599
Available from: 2025-05-21 Created: 2025-05-21 Last updated: 2025-05-21Bibliographically approved

Open Access in DiVA

fulltext(3556 kB)580 downloads
File information
File name FULLTEXT01.pdfFile size 3556 kBChecksum SHA-512
7ec70365be4b4cd1132dd2c73d96375f4df9fa0812003ce13465edc3e7a0d9d835da4462e6a2582d5f6623ae309833aef07320acf0364b14da3b878387792fde
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Niessen, JanisArendt, NathalieSjöblom, MarkusDubbelboer, Ilse R.Hedeland, MikaelLennernäs, HansDahlgren, David

Search in DiVA

By author/editor
Niessen, JanisArendt, NathalieSjöblom, MarkusDubbelboer, Ilse R.Hedeland, MikaelLennernäs, HansDahlgren, David
By organisation
Department of Pharmaceutical BiosciencesDepartment of Medical Cell BiologyResearch group Markus Sjöblom/Olof NylanderAnalytical Pharmaceutical Chemistry
In the same journal
European journal of pharmaceutics and biopharmaceutics
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 580 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 345 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf